Over the forecast period, the worldwide dengue vaccine market is expected to rise due to rising dengue prevalence. According to the Pan American Health Organization, a total of 1,191,815 cases of dengue fever were recorded in the Americas region between epidemiological weeks 1 and 22 of 2019, with 546,589 cases being laboratory-confirmed and 5,599 being categorised as severe dengue.
Furthermore, market expansion is likely to be aided by R&D of live attenuated vaccines. Dengvaxia, for example, was licenced by the US Food and Drug Administration in May 2019 for the prevention of dengue fever caused by all dengue virus serotypes. It's a chimaera vaccine developed with recombinant DNA that's live attenuated and tetravalent.
Click here for Dengue Vaccine Market Report: